Bedford, Mass.-based Access Vascular’s HydroPICC is indicated for reduced thrombus accumulation. The catheter body is composed of biocompatible biomaterial, instead of the standard polyurethane as the material for the body.
The company said it has demonstrated a 97% reduction in thrombus accumulation, compared to traditional polyurethane PICCs.
Access said future applications aside from the HydroPICC include midlines, dialysis catheters, ports, and other devices.
“We are thrilled to be recognized by Premier as a breakthrough technology and are excited about the opportunity to introduce HydroPICC to Premier’s members,” Access founder & CEO James Biggins said in prepared remarks. “This contract will accelerate our commercialization by allowing us to get HydroPICC into the hands of a wider range of customers.”